To analyze whether C1ORF112 genetic alterations have an impact on clinical outcomes of cancer patients, we discovered that C1ORF112 amplification could be a risk factor for patients with liver cancer, while C1ORF112 mutation may be protective in UCEC patients. This evidence concerns the gene FIRRM and cancer.